10-K · April 30, 2026
Catalyst Pharmaceuticals reported solid financial performance for the year ended December 31, 2025, with significant revenue growth and improved profitability metrics. The company achieved total revenues of $573.5…
Earnings analysis · 10-Q
CPRX earnings analysis
Filed May 11, 2026 · Our reading of the company's report
The latest report
Catalyst Pharmaceuticals reported a strong Q1 2026 with revenue of approximately $149.4 million, reflecting a 5.6% increase year-over-year. However, EPS of $0.50 came in below estimated expectations of $0.63, indicating…
Read full summary
Catalyst Pharmaceuticals reported a strong Q1 2026 with revenue of approximately $149.4 million, reflecting a 5.6% increase year-over-year. However, EPS of $0.50 came in below estimated expectations of $0.63, indicating pressure from generics impacting FYCOMPA® while FIRDAPSE® and AGAMREE® showed robust growth.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $0.5
What stood out
-
Revenue Growth
Total revenue increased by $7.9 million to $149.4 million compared to $141.4 million in Q1 2025.
-
FIRDAPSE® Performance
Product revenue for FIRDAPSE® rose by 18.1% to $98.9 million from $83.7 million year-over-year.
-
AGAMREE® Revenue Increase
AGAMREE® sales surged by 66.6% to $36.7 million, up from $22.0 million.
-
Improved Net Income
Net income increased to $63.7 million in Q1 2026 from $56.7 million in Q1 2025.
-
Cash Position Strength
Cash and cash equivalents increased to $755.9 million from $709.2 million at year-end.
-
Operating Cash Flow
Net cash provided by operating activities was approximately $59.6 million for Q1 2026.
What to watch
-
FYCOMPA® Revenue Decline
FYCOMPA® revenue dropped by 61.3% to $13.8 million due to the entry of generic competition after losing exclusivity.
-
Acquisition Dependency
Upcoming merger with Angelini Pharma has risks associated with regulatory approvals and successful integration.
-
Litigation Costs
Ongoing patent litigations, including a recently settled agreement with Hetero, may result in additional costs.
Management's outlook
No quantitative guidance provided; management's outlook seen as contingent on the completion of the proposed merger.
Earlier filings 4
10-K · February 25, 2026
Catalyst Pharmaceuticals presents a commercial-stage rare disease platform anchored by three marketed products (FIRDAPSE®, AGAMREE®, FYCOMPA®) and a growing commercial footprint. AGAMREE® materially ramped in 2025 (net…
10-Q · November 8, 2023
Catalyst reported strong product revenue growth to $102,688,000 for Q3 2023 (up from $57,244,000 in Q3 2022) but recorded a GAAP operating loss of $(37,188,000) and a net loss of $(30,764,000) for the quarter, driven by…
10-Q · May 10, 2022
Catalyst reported Q1 revenue of $43.089M (vs $30.205M year-ago) driven by product sales of $43.033M. Profitability improved materially: operating income was $17.366M and net income $13.241M (diluted EPS $0.12 vs $0.07…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.